MAPT and Parkinson disease: Although CSF biomarkers, such as α-Syn, Aβ42, t-tau, and p-tau, are demonstrated to be informative for PD risk [40], they generally do not offer additional predictive power when sufficient information (i.e., clinical assessments and PRS) are already included in the model.